» Articles » PMID: 33713588

Stability of Sputum Inflammatory Phenotypes in Childhood Asthma During Stable and Exacerbation Phases

Overview
Date 2021 Mar 13
PMID 33713588
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Management strategies based on airway inflammation phenotypes are increasingly used for adults with asthma. While sputum-based phenotypes are relatively stable in adults with asthma, there is little such data in childhood asthma. Hence, we aimed to evaluate the stability of sputum inflammatory phenotypes in children with asthma both in the stable and during exacerbation phases.

Methods: Sputum cellularity data from two previous prospective studies involving children with asthma were re-evaluated and categorized into two inflammatory phenotypes: eosinophilic (>2.5% eosinophils) and noneosinophilic (≤2.5% eosinophils). Baseline values and follow-up sputum inflammatory phenotype classification were compared in children with asthma during stable and exacerbation phases.

Results: Thirteen of 32 children (41%) with stable asthma demonstrated a change in sputum inflammatory phenotype 8 weeks later. In a different second cohort, both sputum eosinophils and neutrophils percentages increased and peaked on Day 1 of asthma exacerbation, but compared with baseline, 22% (2/9) and 13% (1/8) of these children had their sputum phenotype categorization changed on Day 1 and Day 3 of exacerbation, respectively.

Conclusion: In children with asthma, sputum inflammatory phenotypes are variable in both stable and exacerbation phases, in contrast to data in adults.

Citing Articles

Clinical Significance of Combined Detection of CCL22 and IL-1 as Potential New Bronchial Inflammatory Mediators in Children's Asthma.

Cui L, Song X, Peng Y, Shi M Immun Inflamm Dis. 2024; 12(11):e70043.

PMID: 39508721 PMC: 11542289. DOI: 10.1002/iid3.70043.


A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate-Severe Asthma.

Garcia G, van Dijkman S, Pavord I, Singh D, Oosterholt S, Fulmali S Adv Ther. 2024; 41(8):3196-3216.

PMID: 38916810 PMC: 11263416. DOI: 10.1007/s12325-024-02914-w.


Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies.

Liu T, Woodruff P, Zhou X Eur Respir J. 2024; 64(2).

PMID: 38697650 PMC: 11325267. DOI: 10.1183/13993003.00826-2023.


Endotypes of Paediatric Cough-Do They Exist and Finding New Techniques to Improve Clinical Outcomes.

OFarrell H, Kok H, Goel S, Chang A, Yerkovich S J Clin Med. 2024; 13(3).

PMID: 38337450 PMC: 10856076. DOI: 10.3390/jcm13030756.


Assessment of Airway Inflammation by Induced Sputum in Children with Persistent Asthma.

Srivastava C, Saroj A, Kumar S, Rao S Indian J Pediatr. 2024; 91(5):519.

PMID: 38194205 DOI: 10.1007/s12098-024-05020-5.